Form 4: Day One Biopharmaceuticals Director Receives Significant Equity Grants

John A. Josey, a Director at Day One Biopharmaceuticals, Inc., was granted 22,500 stock options and 15,000 deferred restricted stock units, aligning his interests with shareholder value.

Summary

• John A. Josey, a Director of Day One Biopharmaceuticals, Inc. (DAWN), received new equity grants on June 2, 2025.
• The grants include 22,500 stock options with an exercise price of $7.01 per share.
• These stock options will vest as to 1/12th of the total grant on each monthly anniversary, beginning July 2, 2025, contingent on Mr. Josey's continued service.
• The stock options have an expiration date of June 1, 2035.
• Additionally, Mr. Josey was granted 15,000 deferred Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock for no consideration.
• The RSUs will vest 100% on the earlier of June 2, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to continued service.
• Upon vesting, the RSUs will automatically convert into an equal number of deferred stock units, which will be settled for shares on the earlier of calendar year 2030 or Mr. Josey's separation from the Issuer, with earlier settlement possible under specific conditions like death, disability, or unforeseeable emergency.

Sentiment

Score: 5

Explanation: This is a routine SEC Form 4 filing reporting insider equity grants, which is a neutral event in itself. It reflects standard compensation practices and aligns director interests with shareholders, but does not provide information on company performance or strategic shifts that would significantly alter sentiment.

Positives

• The granting of stock options and restricted stock units to a director aligns their financial interests directly with the long-term performance and shareholder value of Day One Biopharmaceuticals, Inc.
• Equity compensation is a standard practice that can incentivize directors to contribute to the company's growth and success.

Risks

• Future share issuance upon the exercise of stock options and settlement of RSUs could lead to dilution for existing shareholders.
• The value of the equity grants is subject to the future market price of Day One Biopharmaceuticals' common stock, introducing market risk for the recipient.
• Vesting of the equity is contingent on continued service, meaning the director must remain with the company to fully realize the benefits.

Future Outlook

The document outlines future vesting schedules for stock options and restricted stock units, indicating a long-term commitment and incentive structure for the reporting director. The settlement of RSUs is deferred until 2030 or earlier upon separation, aligning long-term interests.

Industry Context

The granting of stock options and restricted stock units is a common and standard practice for compensating directors and executives in the biotechnology and pharmaceutical industries. This form of compensation is widely used to attract and retain talent, and to align the interests of leadership with those of shareholders by tying compensation to company performance and stock value.

Comparison to Industry Standards

• The structure of equity compensation, including a mix of stock options and restricted stock units with multi-year vesting schedules, is consistent with typical compensation packages for directors in publicly traded biotechnology companies like Day One Biopharmaceuticals.
• The vesting schedule for stock options (monthly over 12 months) and RSUs (cliff vesting after one year or at the next annual meeting) are common mechanisms to ensure continued service and long-term alignment.
• The deferral of RSU settlement until 2030 or separation is a common strategy to comply with tax regulations and further incentivize long-term commitment.

Related Party Transactions

• The document details equity grants (22,500 stock options and 15,000 deferred restricted stock units) from Day One Biopharmaceuticals, Inc. to John A. Josey, a Director of the company. These are considered related party transactions as they involve compensation to an insider.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to more focused efforts on increasing shareholder value. However, future exercise/settlement could lead to minor dilution.
• Employees: No direct impact mentioned, but standard equity compensation practices can contribute to a positive corporate culture regarding incentives.
• Management: The grants are part of the compensation structure for a director, incentivizing long-term commitment and performance.

Next Steps

• Continued vesting of 22,500 stock options on a monthly basis starting July 2, 2025, subject to continued service.
• Vesting of 15,000 RSUs on the earlier of June 2, 2026, or the 2026 annual meeting of stockholders, subject to continued service.
• Automatic conversion of vested RSUs into deferred stock units.
• Settlement of deferred stock units into common stock on the earlier of calendar year 2030 or the reporting person's separation from the Issuer.

Key Dates

Keywords

Day One Biopharmaceuticals, DAWN, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, RSU, Equity Compensation, Director Compensation, Beneficial Ownership, Corporate Governance